Description
Trust Badges:
- Phase 3 Proven (REDEFINE 1 & 2)
- Batch-COA Available (QR on vial & page)
- Secure Payments (Card + Crypto)
- Fast Canada Shipping
Science & Mechanism (accordion)
How It Works:
CagriSema combines semaglutide (GLP‑1 receptor agonist) and cagrilintide (amylin analog) for synergistic appetite suppression via both hypothalamic and brainstem pathways—resulting in enhanced metabolic and satiety regulation.
Clinical Evidence:
The REDEFINE 1 Phase III trial (68 weeks, N=3,417, obesity without diabetes) demonstrated:
- Mean body weight reduction: 20.4% on ITT, 22.7% in adherence analysis. Placebo: 2.3%.
- ≥25% weight loss: 40.4% of participants; ≥30%: 23.1%.
A separate study (REDEFINE 2, with T2D patients) showed:
- Mean loss: 13.7% on ITT; 15.7% with full adherence; placebo: ~3%.
Reconstitution & Dosing Tables (Weight Loss Peptides)
CagriSema (2.4 mg + 2.4 mg vial + 2 mL BAC water)
-
Final concentration = 1.2 mg/mL of each compound.
-
Insulin syringe = 12 mcg per unit of each peptide.
Dose (each)
|
Volume (mL)
|
Syringe Units
|
0.25 mg
|
0.21 mL
|
21 units
|
0.5 mg
|
0.42 mL
|
42 units
|
1.0 mg
|
0.83 mL
|
83 units
|
1.7 mg
|
1.42 mL
|
142 units
|
2.4 mg
|
2.00 mL
|
200 units
|
Dosing Guide (Educational)
Titration (Weekly SubQ):
| Week Range |
Dose (mg each) |
| 1–4 |
0.25 mg |
| 5–8 |
0.5 mg |
| 9–12 |
1.0 mg |
| 13–16 |
1.7 mg |
| 17+ |
2.4 mg |
Note: Start low for tolerance; escalate every 4 weeks. Most users maintain at 2.4 mg weekly for optimal effect.
Reconstitution Guide (Single vial)
- Add 2 mL bacteriostatic water → 1 mg per 0.166 mL (10 units on insulin syringe).
- 0.25 mg dose = ~25 units; 2.4 mg = full 2 mL.
Storage & Handling
- Store lyophilized vial refrigerated (2–8 °C).
- After reconstitution, refrigerate and use within 30 days. Protect from light.
Disclaimers & Legal Copy
- Educational purposes only. Not approved by Health Canada or FDA for weight-loss optimization.
- Always consult with healthcare provider prior to use.
FAQ Section
- How does this compare to semaglutide alone?
CagriSema outperforms semaglutide, delivering ~6–8% more weight loss in trials.
- Is the combo safer or just more effective?
Safety comparable to GLP-1 class; most side effects were mild/moderate GI symptoms.
- Can doses be titrated separately?
The pre-blended vial simplifies use. For separate titration, consider bundled vials (Semaglutide + Cagrilintide).
Quick Summary Block
| Feature |
Details |
| Mechanism |
GLP-1 + Amylin dual agonism |
| Peak Loss |
Up to 22.7% (ITT/adherence) |
| ≥20% Loss Rate |
~60%, ≥30% by ~23% of users |
| Dosing |
Titration over 4-week increments to 2.4 mg |
| Testing |
HPLC/MS COA; QR access per batch |
📚 Cagrilintide + Semaglutide References
- NEJM REDEFINE-1 (Phase 3 Trial, 68 weeks, adults without diabetes) — 22.7% mean weight reduction
🔗 https://mediacenteratypon.nejmgroup-production.org/NEJMoa2502082.pdf
- Press Release (NEJM publication) — 22.7% weight loss, 40% ≥25% loss, 23% ≥30% loss
🔗 https://www.prnewswire.com/news-releases/cagrisema-2-4-mg–2-4-mg-demonstrated-22-7-mean-weight-reduction-in-adults-with-overweight-or-obesity-in-redefine-1–published-in-nejm-302487770.html
- Applied Clinical Trials — Trial summary and efficacy data
🔗 https://www.appliedclinicaltrialsonline.com/view/cagrilintide-semaglutide-weight-loss
- The Innovation (mechanism review, dual agonism pathways)
🔗 https://www.the-innovation.org/article/doi/10.59717/j.xinn-med.2025.100150
- AP News — 23% ≥30% loss and long-term efficacy
🔗 https://apnews.com/article/2df62bb4f1270bdfbeed61b7661f535e
- American Diabetes Association (REDEFINE-2, patients with diabetes) — 13.7–15.7% mean loss
🔗 https://diabetes.org/newsroom/press-releases/cagrisema-demonstrates-significant-weight-loss-adults-obesity
Reviews
There are no reviews yet.